ArticleBalkan medical journal2017
Increased Risk of Metabolic Syndrome in Patients with Vitiligo.
Article in Balkan medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.Annals of medicine · 2024Pooled it
- Risk of metabolic syndrome in patients with lichen planus: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Markers of Systemic Metabolic Dysfunction in Vitiligo and Their Potential Role in Disease Pathogenesis: A Narrative Review.Health science reports · 2026Article
- Vitiligo in the United States: A 10-year study of patient characteristics, comorbidities, and treatment patterns.Dermatology online journal · 2026Article
- Dysregulated Intracellular Signaling in the Pathogenesis of Vitiligo: An Update on Emerging Therapeutic Strategies.Biomedicines · 2025Review
- Metabolic syndrome and dermatological diseases: association and treatment.Nutrition & metabolism · 2025Review
- Associations and mediators between vitiligo and cardiovascular diseases: a Mendelian randomization study.Scientific reports · 2025Article
- The association between metabolic syndrome and vitiligo: a systematic review.Postepy dermatologii i alergologii · 2025Review
- Metabolic anomalies in vitiligo: a new frontier for drug repurposing strategies.Frontiers in pharmacology · 2025Article
- Laboratory and clinical haemostatic aberrations in primary dermatologic disease: A review.Thrombosis journal · 2024Review
- Markers of Metabolic Abnormalities in Vitiligo Patients.International journal of molecular sciences · 2024Article
- Circadian clock gene expression and polymorphism in non-segmental vitiligo.Molecular biology reports · 2024Article
- Association between metabolic syndrome and prevalent skin diseases: A systematic review and meta-analysis of case-control studies.Health science reports · 2023Article
- Vitiligo and insulin resistance as a component of metabolic syndrome: an analysis.Postepy dermatologii i alergologii · 2023Review
- Beyond skin white spots: Vitiligo and associated comorbidities.Frontiers in medicine · 2023Review
- Vitiligo and Metabolic Syndrome: Systematic Review and Meta-Analysis.JMIR dermatology · 2022Review
- Potential Role of Chronic Physical Exercise as a Treatment in the Development of Vitiligo.Frontiers in physiology · 2022Article
- Immunometabolism in the pathogenesis of vitiligo.Frontiers in immunology · 2022Review
- Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.Clinical reviews in allergy & immunology · 2021Review
- Metabolic Comorbidities in Vitiligo: A Brief Review and Report of New Data from a Single-Center Experience.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory and immune processes can be triggered in vitiligo due to a decreased number of melanocytes and their anti-inflammatory effects. Because of the systemic nature of vitiligo, metabolic abnormalities such as insulin resistance and lipid profile disturbances as well as skin involvement may be observed in vitiligo.
aimsTo investigate the association between metabolic syndrome and vitiligo. STUDY
designCase-control study.
methodsThe demographic, clinical and laboratory features in the subjects were compared according to presence of vitiligo and metabolic syndrome [patients (n=63) vs. gender-age matched controls (n=65) and metabolic syndrome positive (n=38) vs. negative (n=90)]. A logistic regression analysis was also used.
resultsWe identified metabolic syndrome in 24 (38.1%) subjects with vitiligo and 14 (21.5%) subjects without vitiligo (p=0.04). Active vitiligo, segmental vitiligo, an increased duration of vitiligo and an increased percentage in the affected body surface area were determined to be independent predictors of metabolic syndrome [activity of vitiligo: p=0.012, OR (95% CI)=64.4 (2.5-1672); type of vitiligo: p=0.007, OR (95% CI)=215.1 (4.3-10725.8); duration of vitiligo: p=0.03, OR (95% CI)=1.4 (1.1-2.0); percentage of affected body surface area: p=0.07, OR (95% CI)=1.2 (0.98-1.5)].
conclusionThe risk of developing metabolic syndrome is increased in patients with vitiligo. The poor clinical features of vitiligo, such as active, extended and segmental vitiligo with an increased duration of time, are independent predictors for developing metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.